4.6 Review

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6

Journal

CANCERS
Volume 13, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13112600

Keywords

tumor immunology; tumor-promoting function; alternative and druggable cancer immune checkpoint; transcriptional repressor of CD4(+) and CD8(+) effector but not regulatory T cell functions

Categories

Funding

  1. Austrian Science Fund (FWF) [P30324-B21, P31383-B30, P34368-B, TAI 88]
  2. ERC ADG [786462-HOPE]
  3. Austrian Central Bank Jubilaumsfonds project [17551]
  4. Medical University Innsbruck
  5. Austrian Science Fund (FWF) [P30324, P34368, P31383] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

The text explores the potential of NR2F6 as an emerging target for cancer immunotherapy, aiming to increase patient response rates and extend treatment options. Future therapies may combine surface receptor and intracellular protein targets.
Simple Summary The most successful strategies for solid cancer immunotherapy have centered on targeting the co-stimulatory and co-inhibitory T cell molecules that regulate T cell activation. Although immunotherapy that targets surface receptors such as CTLA-4 and/or PD-1 with recombinant antibodies has been a game changer for cancer treatment, a sizeable subset of patients still fail to respond to, and even fewer patients are cured by, these therapy regimens. Here, we discuss the unique potential of NR2F6 as an emerging target for cancer immunotherapy to significantly increase response rates of cancer patients and/or to extend treatment to a broader range of cancer types. Additional therapeutic targets suitable for boosting anti-tumor effector responses have been found inside effector CD4(+) and CD8(+) T cells. It is likely that future treatment options will combine surface receptor and intracellular protein targets. Utilizing germline gene ablation as well as CRISPR/Cas9-mediated acute gene mutagenesis, the nuclear receptor NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) has been firmly characterized as such an intracellular immune checkpoint in effector T cells. Targeting this receptor appears to be a strategy for improving anti-tumor immunotherapy responses, especially in combination with CTLA-4 and PD-1. Current preclinical experimental knowledge firmly validates the immune checkpoint function of NR2F6 in murine tumor models, which provides a promising perspective for immunotherapy regimens in humans in the near future. While the clinical focus remains on the B7/CD28 family members, protein candidate targets such as NR2F6 are now being investigated in laboratories around the world and in R&D companies. Such an alternative therapeutic approach, if demonstrated to be successful, could supplement the existing therapeutic models and significantly increase response rates of cancer patients and/or expand the reach of immune therapy regimens to include a wider range of cancer entities. In this perspective review, the role of NR2F6 as an emerging and druggable target in immuno-oncology research will be discussed, with special emphasis on the unique potential of NR2F6 and its critical and non-redundant role in both immune and tumor cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available